Abstract
Beta thalassemia major (TM) is the most frequent form of transfusion-dependent inherited anemia in India. The thalassemia syndromes exhibit enormous variability in their genetic basis and phenotypic expression. The authors recommend that the diagnosis of TM or non-transfusion-dependent thalassemia (NTDT) should not be based on a one-time assessment. Many patients have a chronic anemia that is not severe enough to justify regular transfusions, but the clinical course can evolve with age. Continued observation may reveal that some patients who are considered NTDT will benefit from transfusions later in life. Clinical decision making can be influenced by the perceived difficulty in access to a safe blood supply and the cost of therapy. Here, authors present selected case scenarios that address common issues in the management of TM or NTDT. The recommendations are based on published evidence where available or on the authors’ shared experience. Among the topics under discussion are deciding when to start regular transfusions, the role of hydroxyurea in TM, the procedure for blood administration, the use of deferasirox for chelation and monitoring of side effects, the role of splenectomy, and the prospects for gene therapy. In order to achieve an optimal outcome with blood transfusions and chelation therapy over the lifetime, it is essential to adhere to the current guidelines for the management of thalassemia.
Similar content being viewed by others
References
Cappellini MD, Cohen A, Porter J, Taher A, Viprakasit V. Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT) [Internet], 3rd ed. Nicosia (CY): Thalassaemia International Federation; 2014. Available at: http://www.ncbi.nlm.nih.gov/books/NBK269382/. Accessed 30 Oct 2017.
Lal A, Sheth S, Gilbert S, Kwiatkowski JL. Thalassemia management checklists: quick reference guides to reduce disparities in the care of patients with transfusion-dependent thalassemia. Blood. 2018;132:2233.
Olivieri NF, Brittenham GM. Management of the thalassemias. Cold Spring Harb Perspect Med. 2013;3:a011767.
Badens C, Joly P, Agouti I, et al. Variants in genetic modifiers of β-thalassemia can help to predict the major or intermedia type of the disease. Haematologica. 2011;96:1712–4.
Cao A, Galanello R. Beta-thalassemia. Genet Med. 2010;12:61–76.
Weatherall DJ. Phenotype-genotype relationships in monogenic disease: lessons from the thalassaemias. Nat Rev Genet. 2001;2:245–55.
Taher AT, Musallam KM, Cappellini MD, Weatherall DJ. Optimal management of β thalassaemia intermedia. Br J Haematol [Internet]. 2011. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21250971. Accessed 3 Feb 2011.
Piga A, Serra M, Longo F, et al. Changing patterns of splenectomy in transfusion-dependent thalassemia patients. Am J Hematol. 2011;86:808–10.
Bansal D. Splenectomy for β-thalassemia major in resource challenged settings: often a hobson’s choice! Indian J Pediatr. 2015;82:1082–3.
Olivieri NF, Muraca GM, O’Donnell A, Premawardhena A, Fisher C, Weatherall DJ. Studies in haemoglobin E beta-thalassaemia. Br J Haematol. 2008;141:388–97.
Bradai M, Abad MT, Pissard S, Lamraoui F, Skopinski L, de Montalembert M. Hydroxyurea can eliminate transfusion requirements in children with severe {beta}-thalassemia. Blood. 2003;102:1529–30.
Musallam KM, Taher AT, Cappellini MD, Sankaran VG. Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia. Blood. 2013;121:2199–212.
Goldberg SL, Giardina PJ, Chirnomas D, Esposito J, Paley C, Vichinsky E. The palatability and tolerability of deferasirox taken with different beverages or foods. Pediatr Blood Cancer. 2013;60:1507–12.
Taher A, Cappellini MD, Vichinsky E, et al. Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Br J Haematol. 2009;147:752–9.
Cohen AR, Glimm E, Porter JB. Effect of transfusional iron intake on response to chelation therapy in -thalassemia major. Blood. 2008;111:583–7.
Aydinok Y, Kattamis A, Cappellini MD, et al; HYPERION Investigators. Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload. Blood. 2015;125:3868–77.
Lal A, Porter J, Sweeters N, et al. Combined chelation therapy with deferasirox and deferoxamine in thalassemia. Blood Cells Mol Dis. 2013;50:99–104.
Totadri S, Bansal D, Bhatia P, Attri SV, Trehan A, Marwaha RK. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: a prospective, single center, open-label study. Pediatr Blood Cancer. 2015;62:1592–6.
Chang H-H, Lu M-Y, Liao Y-M, et al. Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent β-thalassemia. Pediatr Blood Cancer. 2011;56:420–4.
Cappellini MD. Long-term efficacy and safety of deferasirox. Blood Rev. 2008;22:S35–41.
Díaz-García JD, Gallegos-Villalobos A, Gonzalez-Espinoza L, Sanchez-Niño MD, Villarrubia J, Ortiz A. Deferasirox nephrotoxicity—the knowns and unknowns. Nat Rev Nephrol. 2014;10:574–86.
Food and Drug Adminstration. Exjade: full prescribing information [Internet]. 2019. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021882s031lbl.pdf. Accessed 28 Jul 2019.
Lal A, Wong TE, Andrews J, et al. Transfusion practices and complications in thalassemia. Transfusion. 2018;58:2826–35.
Vichinsky E, Neumayr L, Trimble S, et al. Transfusion complications in thalassemia patients: a report from the Centers for Disease Control and Prevention (CME). Transfusion. 2014;54:972–81.
Dhawan HK, Kumawat V, Marwaha N, et al. Alloimmunization and autoimmunization in transfusion dependent thalassemia major patients: study on 319 patients. Asian J Transfus Sci. 2014;8:84–8.
Pahuja S, Pujani M, Gupta SK, Chandra J, Jain M. Alloimmunization and red cell autoimmunization in multitransfused thalassemics of Indian origin. Hematology. 2010;15:174–7.
Fucharoen S, Weatherall DJ. The hemoglobin E thalassemias. Cold Spring Harb Perspect Med. 2012;2:a011734.
Olivieri NF, Pakbaz Z, Vichinsky E. Hb E/beta-thalassaemia: a common & clinically diverse disorder. Indian J Med Res. 2011;134:522–31.
Colah RB, Gorakshakar A. Control of thalassemia in India. Thalassemia Reports [Internet] 2014;4. Available at: http://www.pagepressjournals.org/index.php/thal/article/view/thal.2014.1955. Accessed 30 Sept 2014.
Thompson AA, Walters MC, Kwiatkowski J, et al. Gene therapy in patients with transfusion-dependent β-thalassemia. New Engl J Med. 2018;378:1479–93.
McClain LE, Flake AW. In utero stem cell transplantation and gene therapy: recent progress and the potential for clinical application. Best Pract Res Clin Obstet Gynaecol. 2016;31:88–98.
Wang H, Georgakopoulou A, Psatha N, et al. In vivo hematopoietic stem cell gene therapy ameliorates murine thalassemia intermedia. J Clin Invest. 2019;129:598–615.
Anurathapan U, Hongeng S, Pakakasama S, et al. Hematopoietic stem cell transplantation for homozygous β-thalassemia and β-thalassemia/hemoglobin E patients from haploidentical donors. Bone Marrow Transplant. 2016;51:813–8.
Sun Q, Wu B, Lan H, et al. Haploidentical haematopoietic stem cell transplantation for thalassaemia major based on an FBCA conditioning regimen. Br J Haematol. 2018;182:554–8.
Fung EB, Aguilar C, Micaily I, Haines D, Lal A. Treatment of vitamin D deficiency in transfusion-dependent thalassemia. Am J Hematol. 2011;86:871–3.
Office of Dietary Supplements. Calcium: fact sheet for health professionals [Internet]. Available at: https://ods.od.nih.gov/factsheets/Calcium-HealthProfessional/. Accessed 28 Jul 2019.
Centers for Disease Control. Vaccination of Adults with Asplenia [Internet]. 2019. Available at: https://www.cdc.gov/vaccines/adults/rec-vac/health-conditions/asplenia.html. Accessed 28 Jul 2019.
Author information
Authors and Affiliations
Contributions
The authors contributed to formulation of questions and discussion of recommended management. DB is the guarantor of this paper.
Corresponding author
Ethics declarations
Conflict of Interest
None.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Lal, A., Bansal, D. Thalassemia: Common Clinical Queries in Management. Indian J Pediatr 87, 75–81 (2020). https://doi.org/10.1007/s12098-019-03065-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12098-019-03065-5